Valuation: Betta Pharmaceuticals Co., Ltd.

Capitalization 18.97B 2.78B 2.36B 2.18B 2.06B 3.81B 259B 3.88B 25.56B 10.02B 124B 10.43B 10.21B 443B P/E ratio 2025 *
33.2x
P/E ratio 2026 * 24.6x
Enterprise value 20.37B 2.99B 2.54B 2.34B 2.21B 4.09B 278B 4.17B 27.44B 10.76B 134B 11.2B 10.97B 475B EV / Sales 2025 *
5.64x
EV / Sales 2026 * 4.71x
Free-Float
51.51%
Yield 2025 *
-
Yield 2026 * -
1 day-2.26%
1 week-0.09%
Current month+1.08%
1 month-0.16%
3 months-11.47%
6 months-25.06%
Current year-5.61%
1 week 43.39
Extreme 43.39
46.3
1 month 40.1
Extreme 40.1
46.31
Current year 40.1
Extreme 40.1
52.83
1 year 40.1
Extreme 40.1
79.8
3 years 30.43
Extreme 30.43
79.8
5 years 30.43
Extreme 30.43
122
10 years 23.19
Extreme 23.19
160.66
Manager TitleAgeSince
Chief Executive Officer 61 23/08/2013
Director of Finance/CFO 55 31/03/2017
Chief Tech/Sci/R&D Officer 69 01/02/2025
Director TitleAgeSince
Chairman 61 23/08/2013
Director/Board Member 48 22/01/2021
Director/Board Member 57 16/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
-2.26%-0.09%-14.63%-38.19% 2.78B
+2.65%+6.21%+1.84%-28.00% 58.96B
-2.24%-5.89%+11.96%-20.56% 8.3B
+0.66%+9.02%+3.70%+40.00% 5.63B
+0.51%+4.16%-13.92%+75.36% 4.91B
+4.91%+2.23%+68.43%+40.98% 2.83B
-0.91%-0.83%+28.73%+35.06% 2.45B
+1.64%+4.22%+94.53%+1.18% 2.05B
-0.80%-4.25%-2.07%-23.69% 1.95B
-0.97%+8.78%+182.15%+368.57% 1.88B
Average +0.32%+1.43%+36.07%+45.07% 9.17B
Weighted average by Cap. +1.65%+2.60%+10.00%-5.23%

Financials

2025 *2026 *
Net sales 3.61B 529M 450M 415M 391M 726M 49.25B 738M 4.86B 1.91B 23.7B 1.99B 1.94B 84.25B 4.3B 631M 536M 495M 466M 865M 58.69B 880M 5.8B 2.27B 28.24B 2.37B 2.32B 100B
Net income 568M 83.24M 70.69M 65.27M 61.53M 114M 7.75B 116M 765M 300M 3.73B 312M 306M 13.25B 792M 116M 98.6M 91.04M 85.82M 159M 10.8B 162M 1.07B 418M 5.2B 436M 426M 18.48B
Net Debt 1.4B 205M 174M 161M 152M 281M 19.08B 286M 1.88B 739M 9.18B 769M 753M 32.65B 1.28B 188M 160M 148M 139M 258M 17.5B 262M 1.73B 678M 8.42B 706M 691M 29.94B
Logo Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Employees
1,961
Date Price Change Volume
17/04/26 44.07 ¥ -2.26% 7,228,480
16/04/26 45.09 ¥ -1.33% 8,045,859
15/04/26 45.70 ¥ +1.85% 13,374,540
14/04/26 44.87 ¥ +2.91% 11,679,530
13/04/26 43.60 ¥ -1.47% 5,350,442
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
44.07CNY
Average target price
44.58CNY
Spread / Average Target
+1.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300558 Stock